Zeliha Kocak

Publications (2)4.96 Total impact

• Article: A brucellosis case presenting with mass formation suggestive for tumor in soft tissue.

  Hasan Karsen, Hayrettin Akdeniz, Hasan Irmak, Turan Buzgan, M Kasm Karahocagil, Zeliha Kocak, Mahmut Sünnetçioğlu
  [show abstract] [hide abstract]
  ABSTRACT: We report here a 70-year-old female patient who was diagnosed with brucellosis and presented with mass formation resembling a tumor. The mass was protuberant, 10 cm from the skin surface with a diameter of 15 cm, located at the inferior-lateral region of the left scapula. Brucella melitensis was yielded from culture of mass fluid. The patient responded to ceftriaxone, rifampin and doxycycline therapy and recovered without any sequela at the end of surgery and 3 months of medical treatment.
  Southern Medical Journal 12/2007; 100(11):1137-9. · 0.83 Impact Factor
• Article: Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders.

  Zeliha Kocak, Cigdem Ataman Hatipoglu, Gunay Ertem, Sami Kinikli, Abdurrahman Tufan, Hasan Irmak, Ali Pekcan Demiroz
  [show abstract] [hide abstract]
  ABSTRACT: Trimethoprim-sulfamethoxazole (TMP-SMX) is a combination chemotherapeutic agent, a commonly used antibiotic. Adverse drug reactions occur in 6-8% of patients. Although, the most common adverse reactions include mild gastrointestinal distress and cutaneous events, also a wide range of hematological abnormalities have been ascribed to TMP-SMX. We report a 40-year-old male patient who developed an early onset neutropenia, thrombocytopenia, generalised rash and oral candidiasis after 5 days long TMP-SMX therapy. Although generalised rash may seen more and improves with discontinuation of the therapy; severe neutropenia, thrombocytopenia and oral candidiasis are seen very rare and rarely leads to fatality as it was in our case. Despite thrombocyte transfusions, whole blood transfusions, red cell concentrates and filgrastim therapy we lost our patient. We want to underline that although the TMP-SMX combination is usually well tolerated it can also lead to fatal complications.
  The Journal of infection 03/2006; 52(2):e49-52. · 4.13 Impact Factor